ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

Background: Epirubicin combined with docetaxel is the cornerstone of neoadjuvant chemotherapy (NAC) for breast cancer. The efficacy of NAC for luminal A breast cancer patients is very limited, and single nucleotide polymorphism is one of the most important factors that influences the efficacy. Our s...

Full description

Bibliographic Details
Main Authors: Yajie Gong, Nanlin Hu, Li Ma, Wentong Li, Xiang Cheng, Yi Zhang, Ying Zhu, Yang Yang, Xiating Peng, Danyi Zou, Jianbo Tian, Lan Yang, Shufang Mei, Xiaoyang Wang, Chun-han Lo, Jiang Chang, Tieying Hou, Hong Zhang, Binghe Xu, Rong Zhong, Peng Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
luminal A breast cancer
ABTB2
neoadjuvant chemotherapy
epirubicin resistance
single nucleotide polymorphism
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.571517/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.571517/full

Similar Items